India, Nov. 4 -- Shares of UroGen Pharma Ltd. (URGN) are falling 18 percent in Wednesday morning trading after the company announced its third-quarter financial results and updated financial outlook for fiscal 2026.
The company's stock is currently trading at $28.25, down 17.91 percent, over the previous close of $34.40 on the Nasdaq. It has traded between $16.50 and $50.81 in the past one year.
UroGen reported a net loss of $1.5 million compared to $33.3 million in the previous year. Total revenue surged to $89.0 million from last year's $27.5 million, mainly driven by the continued commercial launch of ZUSDURI.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT Ne...